Direct Role of Streptozotocin in Inducing Thermal Hyperalgesia by Enhanced Expression of Transient Receptor Potential Vanilloid 1 in Sensory Neurons

Reddy M. Pabbidi, De-Shou Cao, Arti Parihar, Mary E. Pauza, and Louis S. Premkumar

Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, Illinois (R.M.P., D.-S.C., A.P., L.S.P.); and Department of Medical Microbiology, Immunology and Cell Biology & Department of Internal Medicine/Endocrinology, Metabolism and Molecular Medicine, Southern Illinois University School of Medicine Springfield, Illinois (M.E.P.)

ABSTRACT

Streptozotocin (STZ) is a diabetogenic agent extensively used to induce diabetes and to study complications including diabetic peripheral neuropathy (DPN). While studying the influence of transient receptor potential vanilloid 1 (TRPV1) on DPN in the STZ-induced diabetic mouse model, we found that a proportion of STZ-treated mice was nondiabetic but still exhibited hyperalgesia. To understand the mechanism underlying this phenomenon, dorsal root ganglion (DRG) neurons and stably TRPV1 expressing human embryonic kidney (HEK) 293T cells were used to study the expression and function of TRPV1. Incubation of DRG neurons with STZ resulted in a significant increase in the amplitude of capsaicin-induced TRPV1-mediated current and Ca2+ influx compared with vehicle-treated sister cultures. It was also found that STZ treatment induced higher levels of reactive oxygen species, which was abolished with concomitant treatment with catalase. Treatment of cells with H2O2 mimicked the effects of STZ. Western blot analysis revealed an increase in TRPV1 protein content and phospho p38 (p-p38) mitogen-activated protein kinase (MAPK) levels in DRG of STZ-injected diabetic and nondiabetic hyperalgesic mice compared with control mice. Furthermore, in stably TRPV1-expressing HEK 293T cells, STZ treatment induced an increase in TRPV1 protein content and p-p38 MAPK levels, which was abolished with concomitant treatment with catalase or p38 MAPK inhibitor. These results reveal that STZ has a direct action on neurons and modulates the expression and function of TRPV1, a nociceptive ion channel that is responsible for inflammatory thermal pain.

STZ, a glucosamine-nitrosourea compound obtained from Streptomyces achromogenes, is used as a common tool to induce insulin-dependent diabetes mellitus in rodents to study diabetes-induced complications. One such complication is diabetic peripheral neuropathy (DPN). DPN in rodents and humans is characterized by an early thermal and mechanical hyperalgesia (Courteix et al., 1996; Sugimoto et al., 2000). A direct effect of hyperglycemia contributing to hyperalgesia has been suggested by various studies (Courteix et al., 1996; Chen and Pan, 2002). However, treatment with insulin-like growth factor or direct neuronal delivery of low doses of insulin, insufficient to reduce hyperglycemia, ameliorated diabetic neuropathy suggesting that mechanisms other than hyperglycemia may be involved in the pathogenesis of hyperalgesia (Zhuang et al., 1997; Brussee et al., 2004).

STZ is transported into β cells of the pancreas through glucose transporter GLUT2 and causes DNA damage either by alkylation, by the generation of nitric oxide (NO), or by the generation of peroxynitrite (Turk et al., 1993; Schnell et al., 1994; Kroncke et al., 1995). The DNA strand breaks lead to the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), which synthesizes large amounts of the ADP-ribose polymer, using cellular nicotinamide adenine dinucleotide (NAD+) as a substrate (LeDoux et al., 1988; Delaney et al., 1995; Pieper et al., 1999). A decrease in the intracellular NAD+ levels causes a depletion of ATP, a mechanism that can induce cell death (Berger, 1985). Failure of STZ to induce diabetes in PARP-deficient mice suggests the
important role played by PARP in STZ-induced β cell necrosis (Burkart et al., 1999). Another proposed mechanism of STZ-induced cytotoxic effect is its selective inhibition of N-acetyl-β-D-glucosaminidase, which is highly expressed in pancreatic β cells compared with neurons (Konrad et al., 2001). Inhibition of N-acetyl-β-D-glucosaminidase results in increased glycosylation of proteins, altering their structure and function and leading to the death of β cells (Konrad et al., 2001). In pancreatic β cells, STZ has been shown to produce superoxide anion by inhibiting the Krebs cycle, which will limit the generation of ATP, promoting the death of β cells (Nukatsuka et al., 1990; Sofue et al., 1991; Turk et al., 1993). However, although the effects of STZ are believed to be specific to pancreatic β cells, STZ administration has been shown to adversely affect renal, hepatic, and muscle tissues (Petzold and Svenberg, 1978; Brambilla et al., 1987; Johnston et al., 2007).

Topical application of capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, improves sensory perception in humans with DPN (Forst et al., 2002). In animal models of diabetes, in which DPN manifests as hyperalgesia, the beginning of the experiments.

6 to 10 weeks of age and weighed between 18 and 23 g at the beginning of the experiments.

400, and 1000 μM ATP, and 0.25 mM GTP, with pH adjusted to 7.35 with NaOH. The experiments were conducted in a blind fashion by measuring the PWL in randomly chosen animals from diabetic or control groups. After completing the test, the ear tags were read to place them in the appropriate groups. There were slight gender differences, but they were not statistically significant, therefore male and female mice were grouped together for further analyses.

In Vitro STZ Treatment. To assess the effect of STZ on TRPV1 expression, reactive oxygen species (ROS) production, or cell viability, cultured DRG neurons and stably TRPV1-expressing HEK 293T cells (Puntambekar et al., 2005) were exposed to 10, 40, 100, 300, 400, and 1000 μM STZ. STZ was prepared as a fresh stock solution by dissolving it in 0.1 N citrate buffer, pH 4.5, before adding it to the neuronal medium and incubated for 24 to 72 h. In the experiments that required the exposure of STZ longer than 24 h, the medium was replaced with appropriated doses of STZ. The experimental observations were compared with sister cultures that were treated with 0.1 N citrate buffer.

Electrophysiology. Primary DRG neuronal cultures were prepared from embryonic day 18 rat embryos. Adult pregnant rats were killed with an overdose of isoflurane. DRG were dissected, and the neurons were dissociated by trituration with a fire-polished glass pipette in Hanks’ balanced salt solution (Ca²⁺- and Mg²⁺-free). Neurons were cultured in neurobasal medium (Invitrogen, Carlsbad, CA), supplemented with 1-glutamine and B27 supplement (Invitrogen, Grand Island, NY) and grown on poly-(-lysine)-coated glass coverslips in 24-well plates. Neurons were incubated at 37°C in a humidified atmosphere of 5% CO₂. Neurons were used from 3 days after plating. For whole-cell patch clamp current recordings, the bath solution contained 140 mM sodium gluconate, 2.5 mM KCl, 10 mM HEPES, 1 mM MgCl₂, and 1.5 mM EGTA, with pH adjusted to 7.35 with NaOH, and the pipette solution contained 140 mM potassium gluconate, 5 mM KCl, 10 mM HEPES, 2 mM MgCl₂, 10 mM EGTA, 2 mM ATP, and 0.25 mM GTP, with pH adjusted to 7.35 with NaOH. Ca²⁺-free extracellular solution was used to avoid desensitization and tachyphylaxis of capsaicin-induced currents. The junction potential between the patch pipette and the bath solutions was cancelled before the gigahm seal was formed. The tip of the drug application pipettes was placed within 100 μm of the neurons. Currents were recorded using a WFC-100 patch-clamp amplifier (E.S.F. Electronic, Goettingen, Germany). Data were digitized (VR-10B; InstruTech, Great Neck, NY) and stored in videotapes or directly stored in the computer using a Lab View (National Instruments, Austin, TX) interface. For analysis, data were filtered at 2.5 kHz (−3 dB fre-
frequency with an eight-pole low-pass Bessel filter, LPF-8; Warner Instruments, Hamden, CT) and digitized at 5 kHz. Current amplitudes were measured using Channel 2 Software (kindly provided by Michael Smith, Australian National University, Canberra, Australia). The traces and graphs were plotted using Origin Software (OriginLab Corp., Northampton, MA). Capacitance of the cell was measured manually by using the readout in the WPC-100 amplifier.

Measurement of ROS. ROS production was detected using the dye 2′,7′-dichlorofluorescein diacetate (DCF-DA; Invitrogen). DCF-DA, a nonfluorescent cell-permeant compound, is cleaved by endogenous esterases and the de-esterified product becomes fluorescent upon oxidation by ROS. Cells were incubated with DCF-DA (20 μM) at 37°C for 20 min and washed twice in Hank’s balanced salt solution to reduce nonspecific fluorescence. Fluorescence measurements were carried out using an inverted microscope (DMIRE2; Leica, Plymouth, MN) equipped with a camera (Retiga Ex; Roper Scientific, Victoria, Australia) and the Lambda DG4 wavelength switcher (Sutter Instruments). Fluo-4 was excited at 488 nm, and the emitted fluorescence was filtered with a 535 nm wavelength. The ratio of the fluorescence change represents the change in intracellular Ca2+ concentration.

Ca2+ Imaging. DRG neurons grown on glass coverslips were incubated with Fluo-4 AM (3 μM) (Invitrogen) for 20 min at 37°C and washed with physiological buffer containing 140 mM NaCl, 5 mM HEPES, 2 mM CaCl2, 1 mM MgCl2, 2.5 mM KCl, and 2 mM lido- caine, pH 7.35. The experiments were carried out using a microscope (DMIRE2) attached to a camera (Retiga Ex) and the Lambda DG4 wavelength switcher (Sutter Instruments). Fluo-4 was excited at 488 nm, and the emitted fluorescence was filtered with a 535 ± 25 nm bandpass filter and analyzed using the Sc analytics software. Multiple cells were selected, and the fluorescence of individual cells was tracked. The ratio of the fluorescence change (F/F0), was plotted to represent the change in intracellular Ca2+ levels.

Cell Viability Assay. Coverslips containing embryonic DRG neu-rons were incubated with 15 μl of fluorescein diacetate (FDA; 15 mg/ml) and 15 μl of propidium iodide (PI; 4.6 mg/ml) for 3 min by adding them into 0.5 ml of neurobasal medium. Cells were washed twice with Ca2+-free buffer to prevent nonspecific background fluores-ence. Green fluorescence (λex 488 nm and λem 502 nm wavelength for FDA) for live and red fluorescence (λex 535 nm and λem 590–615 nm wavelengths for PI) for dead cells were observed using a microscope (DMIRE2) equipped with a camera (Retiga Ex) and the Lambda DG4 wavelength switcher (Sutter Instruments) and were analyzed using Sc analytics software. At least five to six independent fields were chosen for analysis for each condition. The percentage of survival or viability of DRG neurons was calculated for different concentrations of STZ.

Western Blot. Mice were sacrificed 1 week after STZ treatment, and DRG were removed and placed in a lysis buffer (0.1% SDS, 1% Triton X-100, 1% deoxycholate, protease, and phosphatase inhibitor cocktail, 1:100; Sigma, St. Louis, MO), homogenized, and centrifuged. Stably TRPV1-expressing HEK 293T cells were cultured as described previously (Puntambekar et al., 2005). TRPV1-expressing HEK cells were scraped into a 400-μl lysis buffer and centrifuged. The protein concentration was measured by the bicinchoninic acid assay. Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to the nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). Membranes were probed overnight with rabbit anti-p38, phospho-p38 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA), β-Actin (1:200; Sigma), or goat anti-TRPV1 (1:100; Santa Cruz Biotechnology) antibodies followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG or rabbit anti-goat IgG (1:10,000, Santa Cruz Biotechnology) for 1 h. After incubation with enhanced chemiluminescence reagents (Santa Cruz Biotechnology), membranes were scanned using the Hitachi genetic systems (Hitachi Software Engineering, Tokyo, Japan), and blots were analyzed using GeneTools Analysis Software (SynGene, Fredrick, MD).

Data Analysis. For behavioral experiments, mixed model analy-sis was performed using SAS/STAT software (SAS Institute, Cary, NC), which included both fixed events (age and time after diabetes onset) and random events (number of subjects) with repeated mea-sures of analysis of variance. The comparisons were made between control group and diabetic groups. Data are shown as mean ± S.E.M. Data are considered significant at p < 0.05.

Results

Alterations in Thermal Pain Sensitivity in STZ-Injected Diabetic Mice. STZ is commonly used to induce type 1 diabetes in rodents for the study of DPN because disease induction is both rapid and reliable. In this study, we ob-served the STZ-treated mice for a period of 7 to 9 weeks after the onset of diabetes. Ins-HA.D2 single transgenic mice were injected with a single dose of STZ (200 mg/kg). After STZ treatment, blood glucose levels were significantly elevated (70–75% of the mice) by the first week after treatment and remained elevated for the course of the study (preinjection, 157 ± 4.4; week 1 STZ, 503.5 ± 24.6; week 7 STZ, 574.7 ± 22.6 mg/dl, n = 11) compared with control vehicle-injected mice (preinjection, 157 ± 6.1; week 1 control, 183.6 ± 2.2; week 7 control, 170 ± 2 mg/dl, n = 6, p < 0.001) (Fig. 1A). As the disease progressed, the body weights of STZ-treated animals remained stagnant, whereas the body weights of control animals increased steadily (STZ week 1, 22.9 ± 0.5; STZ week 6, 21.2 ± 0.6, g, n = 11, p < 0.001; control week 1, 22.1 ± 0.2; control week 6, 26.2 ± 0.3 g, n = 6) (Fig. 1B).

Then the mice were tested for thermal pain sensitivity by measuring the PWL using a hot plate maintained at 52 ± 0.3°C. An early phase of thermal hyperalgesia occurred between 1 and 3 weeks after STZ treatment, which paralleled the onset of hyperglycemia (control week 2, 8.9 ± 0.5 s, n = 19; diabetic week 2, 7.1 ± 0.4 s, n = 33, p < 0.001) (Fig. 1C). Hyperalgesia was followed by a phase of hypoalgesia (control week 8, 9 ± 0.8 s, n = 19, diabetic week 8, 13.4 ± 0.7 s, n = 8, p < 0.001) (Fig. 1C). Together these results indicate that STZ-induced diabetic mice exhibited an initial phase of hyperalgesia followed by a phase of hypoalgesia.

Alterations in Thermal Pain Sensitivity in STZ-Injected Nondiabetic Mice. A proportion (20–25%) of STZ-injected mice did not become diabetic as indicated by the blood sugar levels (<300 mg/dl), but these mice exhibited thermal hyperalgesia. This was further confirmed by a non-diabetogenic dose of STZ (50 mg/kg). The blood glucose levels were slightly higher compared with vehicle-injected mice (STZ-injected nondiabetic mice, 170 ± 8.8; week 2, 222.4 ± 24.3; week 6, 211.4 ± 19.6 mg/dl, n = 13; vehicle-injected mice, 157 ± 6.1; week 2, 163.8 ± 3.9; week 6, 186 ± 1.6 mg/dl, n = 6) (Fig. 2A). Body weights of STZ-injected nondiabetic and vehicle-injected mice increased steadily (STZ-injected diabetic mice week 1, 23 ± 1; and week 6, 25.2 ± 0.9 g, week 6, 26.2 ± 0.3 g, n = 6)
Incubation of Neurons with STZ Increases TRPV1-Mediated Current Responses. To determine whether STZ has a direct action on neurons, cultured embryonic DRG neurons were incubated for 24 h with different concentrations of STZ (20–400 μM), and capsaicin (1 μM)-induced TRPV1-mediated whole-cell currents were recorded. There was a dose-dependent increase in TRPV1 current at lower concentrations followed by a decrease at higher concentrations. Vehicle-treated sister cultures were used as controls. TRPV1-mediated currents were significantly higher at 20 and 100 μM STZ (control, 1 ± 0.2, n = 10; STZ, 2.0 ± 0.1-fold, n = 10, p < 0.004) and 100 μM STZ (control, 1 ± 0.1, n = 9; STZ, 2.5 ± 0.2-fold, n = 9, p < 0.04), but there was no significant change at 200 μM STZ (control, 1 ± 0.3, n = 10; STZ, 1.1 ± 0.2-fold, n = 10), and a decrease in the current amplitude was observed at 400 μM STZ (control, 1 ± 0.2, n = 6; STZ, 0.6 ± 0.2-fold, n = 6) (Fig. 3B). Typically, small-diameter (<25 μm) neurons responded to capsaicin. Average capacitance of DRG neurons in 100 μM STZ-treated neurons (19.2 ± 1.48 pF, n = 9) did not differ from that of control neurons (21.5 ± 1.7 pF, n = 11). Peak current amplitudes were expressed as current densities (in picoamperes per picofarads) using cell capacitance to normalize the differences in cell size, which was found to be significantly higher at 20 and 100 μM STZ concentrations (control, 1 ± 0.2, n = 10; 20 μM STZ, 1.7 ± 0.2-fold, n = 10, p < 0.004) (control, 1 ± 0.2, n = 9; 100 μM STZ, 2.1 ± 0.2-fold, n = 9; p < 0.05) but not at 200 and 400 μM STZ (Fig. 3C). These results demonstrate that lower concentrations of STZ (20 and 100 μM) induce an increase in TRPV1-mediated currents, whereas higher concentrations (>200 μM) cause a decrease, possibly as a result of reaching toxic concentrations. Elevated TRPV1 currents may be one of the mechanisms by which neuronal excitability increases, contributing to hyperalgesia observed in STZ-injected diabetic and nondiabetic mice.

To corroborate the finding that the treatment of STZ increases TRPV1 function, increases in intracellular Ca2+ in response to application of capsaicin (30 nM) were monitored in cultured DRG neurons loaded with Fluo-4 AM after STZ treatment. The advantage of the Ca2+ imaging technique is that it enables the study of multiple neurons at the same time. As described earlier, sister cultures were used in parallel to determine the effect induced by STZ. We observed a significantly higher TRPV1-mediated Ca2+ influx in embryonic DRG neurons incubated with STZ (40 μM) for 24, 48, and 72 h (Fig. 4, A and B) compared with vehicle-injected mice (vehicle-injected mice week 1, 22.1 ± 0.2; week 2, 65 cells) (Fig. 4C). These results suggest that long-term STZ treatment increases the function of TRPV1.
either by an increase in the membrane expression of TRPV1 or an increase in TRPV1 sensitivity. However, longer exposure to STZ resulted in a decrease in Ca\(^{2+}\) influx, possibly as a result of toxicity, as seen with current recordings (Fig. 3).

We noticed a decrease in TRPV1-mediated current when the neurons were exposed to higher concentrations of STZ (\(>200 \mu\text{M}\)). Studies have suggested that 1 mM STZ induces pancreatic \(\beta\) cell death in vitro (Nukatsuka et al., 1990; Konrad et al., 2001). Based on these studies, we hypothesized that STZ might alter the viability of DRG neurons. To test whether STZ can alter the viability of neurons, we performed a viability assay using live and dead cell staining dyes FDA.

![Fig. 2. Altered thermal pain sensitivity in STZ-injected nondiabetic mice. A, a proportion of STZ-injected mice (▲) did not show elevated blood glucose levels and were similar to vehicle-injected mice (○). B, body weights of both STZ-injected nondiabetic mice (▲) and vehicle-injected mice (○) steadily increased. C, STZ-injected nondiabetic mice (▲) exhibited a phase of thermal hyperalgesia compared with vehicle-injected mice (○). Asterisks represent the significance levels (*, \(p < 0.05\); **, \(p < 0.01\)).](image)

![Fig. 3. TRPV1-mediated currents after incubation of cultured DRG neurons with STZ. A, incubation with lower concentrations of STZ (20 and 100 \(\mu\text{M}\)) for 24 h increased capsaicin (1 \(\mu\text{M}\))-evoked currents recorded from small- to medium-diameter DRG neurons compared with 0.1 N citrate buffer-treated DRG neuronal sister cultures. But at higher concentrations of STZ (\(>200 \mu\text{M}\)), capsaicin-evoked currents decreased. B and C, summary graphs show the fold change in peak current amplitude and current densities in STZ-treated neurons. The number in parenthesis represents the number of cells, and the asterisks represent the significance levels (*, \(p < 0.05\); **, \(p < 0.001\) compared with control).](image)
and PI, respectively. Results of the viability assay suggest that increasing concentrations of STZ decreased the viability of embryonic DRG neurons (200 μM, 26%, n = 180; 400 μM, 27.4%, n = 114; and 1000 μM STZ, 16.4%, n = 64, viable cells) compared with vehicle-treated sister cultures.

**STZ Treatment Induces ROS Production in Cultured DRG Neurons in Vitro.** It has been suggested that short- and long-term treatments of STZ induce myopathy through the ROS-mediated mechanism (Johnston et al., 2007). Likewise, nerve growth factor (NGF) induces TRPV1 expression through NADPH oxidase-dependent ROS pathway (Suzukawa et al., 2000; Puntambekar et al., 2005). Therefore, we determined whether ROS is involved in the STZ-induced increase in TRPV1 currents. Initially, we tested whether a known ROS-generating agent, such as hydrogen peroxide, (H2O2, 25 μM) could increase DCF fluorescence intensity in cultured DRG neurons treated for 24 h. As expected, H2O2 significantly increased DCF fluorescence (data not shown). Next, to determine the role of STZ, we pretreated the cultured embryonic DRG neurons with different concentrations of STZ for 24 h, and changes in ROS were measured. We observed a higher DCF fluorescence intensity with increasing concentrations of STZ (citrate buffer, 1 ± 0.03, n = 170 cells; 100 μM STZ, 1.8 ± 0.04, n = 105 cells, p < 0.0001; 400 μM STZ, 1.77 ± 0.05, n = 75 cells, p < 0.0001) (Fig. 5). These results suggest that STZ treatment induces ROS production in cultured DRG neurons, which might play a role in increasing TRPV1-mediated current through ROS-mediated transcriptional or translational regulation. Although ROS levels were higher even at a higher concentration of STZ (400 μM) treatment, TRPV1-mediated currents showed a reduction (Fig. 3), suggesting that higher levels of ROS may become toxic to neurons.

To further test that ROS is involved in STZ-induced TRPV1 expression and function, we pretreated cultured DRG neurons with H2O2 (25 μM) for 24 h, and TRPV1-mediated whole-cell currents were recorded. There was a significant increase in TRPV1-mediated currents compared with citrate buffer-treated cells (buffer, 1 ± 0.1-fold, n = 8; 25 μM H2O2, 1.7 ± 0.1-fold, n = 8, p < 0.05), whereas treatment with 50 μM H2O2, in fact resulted in a decrease in the current amplitude (50 μM H2O2, 0.63 ± 0.19-fold, n = 8), suggesting a narrow effective range of ROS in modulating TRPV1 responses (Fig. 6, A and B). Peak currents normalized to capacitance (measured in picoproamperes per picofarads) were also found to be increased (buffer, 1 ± 0.1-fold, n = 8; 25 μM H2O2, 2.0 ± 0.1-fold, n = 8, p < 0.002) (Fig. 6C). To further confirm that ROS is involved in STZ-induced TRPV1 expression, cultured DRG neurons were concomitantly treated with catalase (200 U/mI), a ROS scavenger. TRPV1-mediated whole-cell currents recorded from the neurons incubated with STZ (100 μM) + catalase or H2O2 (25 μM) + catalase did not increase the current amplitude (buffer, 1 ± 0.2, n = 9; STZ + catalase, 0.96 ± 0.06-fold, n = 10; buffer, 1 ± 0.2-fold, n = 7; H2O2 + catalase, 1.1 ± 0.2-fold, n = 8). Peak current amplitudes expressed as current densities (measured in picoproamperes per picofarads) were not altered after treatment with catalase (STZ + catalase, 0.94 ± 0.09-fold, n = 8; H2O2 + catalase, 1.07 ± 0.18-fold, n = 8) (Fig. 6, A and B). Average capacitance values of DRG in STZ + catalase-treated neurons (18.5 ± 0.67 pF, n = 8) did not differ from control (18.1 ± 0.7 pF, n = 10). These data implicate that STZ-induced ROS levels are involved in the increase in TRPV1-mediated current.

**Increase in TRPV1 and p-p38 MAPK Levels in Diabetic and Nondiabetic Hyperalgesic Mice.** Activation of MAPKs increases the expression of proteins either by transcriptional or post-translational mechanisms. DRG obtained from STZ-treated diabetic or nondiabetic mice 1 week after injection of STZ were probed with TRPV1 and p-p38 MAPK antibodies. Our results demonstrate an increase in TRPV1 expression (Fig. 4) induced increase in intracellular Ca2+ levels in response to application of capsaicin (30 nM) A, representative images showing capsaicin-influenced influx in cultured DRG neurons. Selected DRG neurons in a coverslip were individually tracked for changes in intracellular Ca2+ levels in response to application of capsaicin (30 nM) A, representative images showing capsaicin-induced increase in intracellular Ca2+ after STZ (40 μM) treatment compared with 0.1 N citrate buffer treatment. The inset shows the enlarged image of one of the neurons pointed with arrows. B, representative traces of changes in fluorescence intensity in a group of STZ-treated neurons (right, n = 9) and buffer-treated neurons (left, n = 11). C, summary graph depicting the fold-increase in fluorescence intensity (F/F0) in STZ-treated neurons compared with buffer-treated cultures. Number in the parenthesis represents the number of cells, and the asterisks represent the significance levels (*, p < 0.05; **, p < 0.01 compared with control). Scale bar, 100 μm.
pared with vehicle-treated mice. In addition, the p-p38 MAPK levels (expressed as a ratio of total p38 MAPK levels) were elevated in STZ-treated diabetic (1.45 ± 0.14-fold; n = 3, p < 0.05) and nondiabetic hyperalgesic mice (1.43 ± 0.05-fold; n = 3, p < 0.05) compared with control mice (Fig. 7). Total p38 MAPK levels remained constant after STZ treatment, indicating that STZ caused an increase in the phosphorylation of p38 MAPK rather than increasing the levels of the substrate.

**Activation of STZ-ROS-p38 MAPK Pathway Promotes TRPV1 Expression.** Previous studies have suggested that JNK and p38 MAPK are strongly activated by ROS or by a mild oxidative shift of the intracellular thiol/disulfide redox state (Abe et al., 1996; Hehner et al., 2000). A similar mechanism is also involved in the NGF-induced increase in TRPV1 expression, in which p38 MAPK is activated by ROS, thereby contributing to hyperalgesia (Ji et al., 2002; Puntambekar et al., 2005). Experiments were conducted using stably TRPV1-expressing HEK 293T cells to determine whether the increase in TRPV1 expression induced by long-term STZ treatment is mediated by the ROS-p38 MAPK pathway. Cells were treated with STZ, ROS-generating and -scavenging agents, and then probed for TRPV1 and p-p38 MAPK. Consistent with our previous results, STZ (100 μM)-treated cells exhibited an elevated TRPV1 expression (1.52 ± 0.13-fold, n = 4, p < 0.01) compared with control mice (Fig. 7). Removal of ROS by catalase (200 U/ml) abolished this increase (1.08 ± 0.02-fold, n = 4, p < 0.05). p-p38 MAPK was also found to be increased in STZ-treated cells (1.25 ± 0.04-fold, n = 4, p < 0.01) but did not increase when treated simultaneously with catalase (0.98 ± 0.04-fold, n = 4, p < 0.05) (Fig. 8B). In support of our findings, we successfully reproduced these results with a ROS-generating agent, H$_2$O$_2$ (25 μM) (TRPV1: H$_2$O$_2$, 1.4 ± 0.1-fold, n = 4, p < 0.01; H$_2$O$_2$ + catalase, 1.01 ± 0.09-fold, n = 4, p < 0.05) (p-p38 MAPK: H$_2$O$_2$, 1.48 ± 0.09-fold, n = 4, p < 0.01; H$_2$O$_2$ + catalase, 0.92 ± 0.06-fold, n = 4, p < 0.05) (Fig. 8C), suggesting that STZ-induced TRPV1 expression is mediated by the ROS-p38 MAPK pathway. To confirm that the effect is mediated by p38 MAPK, we incubated the cells with a p38 MAPK inhibitor, SB203580 (20 μM). The increase in TRPV1 and p-p38 MAPK levels was significantly reduced after treatment with the inhibitor (TRPV1, 1.08 ± 0.11-fold, n = 3, p < 0.05; p-p38 MAPK, 0.95 ± 0.08-fold, n = 3, p < 0.05) (Fig. 8D).

**Fig. 5.** Generation of ROS after incubation of cells with STZ, STZ- or vehicle-treated DRG neurons for 24 h were preloaded with DCF-DA (20 μM), and DCF fluorescence intensity was measured. Summary graph depicting a significant increase in DCF fluorescence intensity in STZ (20–1000 μM)-treated DRG neurons compared with vehicle-treated neuronal sister cultures. Number in the parenthesis represents the number of DRG neurons, and the asterisk represents significance level (*, p < 0.001 compared with control).

**Fig. 6.** STZ-induced increase in TRPV1 current is mimicked by H$_2$O$_2$ and abolished by concomitant treatment with catalase. A, representative traces show that the incubation of neuronal cultures with ROS generating agent H$_2$O$_2$ (25 μM) increased the capsaicin-evoked current amplitude compared with currents recorded from neurons in sister cultures. Higher concentration of H$_2$O$_2$ (50 μM) caused a decrease in current amplitude. The increase in current amplitude induced by STZ and H$_2$O$_2$ was reversed by concomitant treatment with catalase. B and C, summary graphs show the change in current amplitude and current densities after incubation of cultures with H$_2$O$_2$ or STZ or along with catalase. Asterisks represent the significance levels (*, p < 0.05; **, p < 0.01 compared with control).
STZ is a glucosamine nitrosourea compound with diabetogenic properties purported to cause a selective destruction of pancreatic β cells. STZ-induced diabetic mice exhibit two phases of thermal pain sensitivity: an initial phase of hyperalgesia, and a late phase of hypealgesia. However, a proportion (~20–25%) of STZ-treated mice did not become diabetic but became hypealgesic compared with the vehicle-injected group. It was further confirmed that hypealgesia was observed in nondiabeticogenic doses of STZ. However, we could not find a correlation between the degree of hypealgesia and the dose of STZ. Possible reasons for the failure of STZ to induce diabetes are 1) inability to damage all pancreatic β cells as a result of insufficient concentration; 2) faster recovery of damaged pancreatic β cells; and 3) decreased bioavailability as a result of rapid breakdown by the liver enzymes or rapid excretion by the kidneys. A normal gain of body weight in STZ-injected nondiabetic mice and a decrease in the body weight of diabetic mice suggest that STZ-injected nondiabetic mice do not suffer from metabolic derangement. Both time course and the degree of thermal hypealgesia were similar in all STZ-treated mice, regardless of their blood glucose levels after STZ injection. Other investigators have not reported this phenomenon, perhaps because of the common practice of excluding nondiabetic mice from studies. However, it has been reported in a study that ~40 to 60% of rats injected with STZ were nondiabetic but exhibited mechanical hypealgesia and insulinopenia (Romanovsky et al., 2004). It was suggested that insulinopenia itself or consequences of insulinopenia that is independent of hyperglycemia might contribute to mechanical hypealgesia. A direct effect of STZ was ruled out as a possible causative factor of mechanical hypealgesia because insulin-treated STZ-injected diabetic rats became normoglycemic and exhibited attenuated pain sensation (Courteix et al., 1996).

TRPV1 plays a role in both diabetic and inflammatory hypealgesia (Caterina et al., 2000; Hong and Wiley, 2005). STZ destroys pancreatic β cells by elevating the ROS levels (Nukatsuka et al., 1990; Sofue et al., 1991; Turk et al., 1993). In another study, moderate increases in ROS levels have been shown to function as secondary messengers that can influence redox-sensitive signal transduction pathways (Suzukawa et al., 2000). In our in vitro studies, STZ-treated neurons exhibited an increase in TRPV1-mediated currents and an increase in the levels of ROS. By recording TRPV1-mediated whole-cell currents in cultured embryonic DRG neurons treated with ROS-generating and -scavenging agents, we have shown that STZ induces TRPV1 expression through the ROS-mediated pathway. We further observed that STZ also caused an increase in the phosphorylated form of p38 MAPK, suggesting that the increase in the TRPV1 protein expression may involve the ROS-p38 MAPK pathway. However, at higher concentrations of STZ and higher levels of ROS, the effect of toxicity is seen as a decrease in TRPV1 expression and a reduction in cell viability.

Peripheral nerve injury leads to an increase in the expression of brain-derived neurotrophic factor and the α2δ Ca2+ channel subunit through activation of p38 MAPK (Zhou et al., 1999; Luo et al., 2001). A similar mechanism is also involved in NGF-induced increase in TRPV1 expression, in which p38 MAPK is activated by ROS, thereby contributing to hypealgesia (Di et al., 2002; Puntambekar et al., 2005). Ji et al. (2002) have proposed that p38 MAPK activates the translational factor eIF4E via MAPK-interacting kinases 1 and 2 and the phosphorylation of which results in an increased affinity of eIF4E for capped RNA influencing translation. Different oxidative stress-inducing stimuli, such as relatively low concentrations of hydrogen peroxide, UV light, γ-irradiation, and interleukin-1, have been shown to activate the activator protein-1, a transcription factor (Angel and Karin, 1991; Devary et al., 1991; Meyer et al., 1993). Likewise, STZ-ROS-p38 MAPK pathway could increase the activity of transcription factors like activator protein-1, inducing transcription of TRPV1, or it may increase the translation of TRPV1 through elF4E. This could lead to an increase in membrane expression and function of TRPV1, thereby contributing to the hypealgesia observed in STZ-injected nondiabetic mice. Nevertheless, a similar mechanism cannot be ruled out in STZ-injected diabetic mice. In HEK cells stably transfected with TRPV1, treatment of STZ caused a similar increase in TRPV1 and p-p38 MAPK expression suggesting that the effect we observe is post-translational rather than post-transcriptional.

It has been suggested that STZ is transported into β cells through the glucose transporter GLUT2 (Schnedl et al., 1994). It is intriguing that the predominant glucose transporter expressed in the peripheral nervous system is GLUT3. STZ treatment may result in PARP activation, possibly through its direct damaging effects of DNA. PARP activation results in an increased production of poly(ADP-ribose), from

**Fig. 7.** TRPV1 and p38 MAPK levels in DRG of STZ-treated diabetic and nondiabetic hypealgesic mice. DRG collected from control, STZ-treated diabetic, and nondiabetic mice 1 week after STZ or vehicle treatment were probed for TRPV1 and p-p38 MAPK by Western blots. Representative Western blots show elevated TRPV1 and p-p38 MAPK levels in diabetic and nondiabetic hypealgesic mice. Summary graph shows fold increase in TRPV1 and p-p38 MAPK levels calculated as a ratio of β-actin and total p38 MAPK levels, respectively. Asterisk represents the significance levels (*, p < 0.05 compared with control).
which adenine 5'-diphosphoribose is generated using cellular NAD\(^+\) as a substrate (LeDoux et al., 1988; Delaney et al., 1995; Pieper et al., 1999). ADP-ribose is a potent activator of TRPMelastatin 2, which has been suggested to play a role in sensing oxidative stress (Fonfria et al., 2004).

Together, our results suggest that STZ exerts a direct action on neurons altering the expression and function of TRPV1 via the ROS-p38 MAPK pathway-mediated translational regulation. Of course, we cannot rule out the possibility that STZ might exert its effects on other nociceptive ion channels such as the voltage-gated sodium channels and the mechanosensitive channels. Therefore, future studies are needed to address the extent of modulation of other ion channels by direct action of STZ (Hayase et al., 2007). To our knowledge, this is the first report suggesting that STZ might have a direct effect on neurons; thus, caution should be exercised in interpreting data as diabetes- or hypoglycemia-induced while using STZ as a diabetogenic agent.

**Fig. 8.** STZ-induced increase in TRPV1 levels is mediated by ROS-p38 MAPK pathway. Stably TRPV1-transfected HEK 293T cells were treated with STZ (100 \(\mu M\)) or \(\text{H}_2\text{O}_2\) (25 \(\mu M\)) and along with catalase or p38 MAPK inhibitor (SB203580) for 24 h, and Western blots were performed. A, TRPV1 expression in transfected HEK cells and no TRPV1 was detected in nontransfected HEK cells. B, STZ induced an increase in TRPV1 and p-p38 MAPK levels, which was blocked by concomitant treatment with catalase (200 U/ml). C. \(\text{H}_2\text{O}_2\)-induced increase in TRPV1, and p-p38 MAPK levels were blocked by treatment with catalase. D, STZ-induced increase in TRPV1 and p-p38 MAPK levels were blocked by treatment with a p38 MAPK inhibitor SB203580 (20 \(\mu M\)). Right, the summary graphs of TRPV1 and p-p38 MAPK levels. Asterisks represent the significance levels (*, \(p < 0.05\) compared with STZ treatment; **, \(p < 0.01\) compared with control).
Acknowledgments

The TRPV1 cDNA was kindly provided by David Julius (University of California, San Francisco, CA).

References


Devary Y, Gottlieb RA, Laus LF, and Karin M (1991) Rapid and preferential activation of protein kinase 1 (BMK1) is a redox-sensitive kinase.


Address correspondence to: Dr. Louis S. Premkumar, Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 62702. E-mail: lpremkumar@siumed.edu

Downloaded from mpharm.ajph.org at ASHET Journals on June 23, 2017